DelveInsight’s “Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Antibody-mediated Rejection, historical and forecasted epidemiology as well as the Antibody-mediated Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Antibody-mediated Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody-mediated Rejection Market Forecast
Some of the key facts of the Antibody-mediated Rejection Market Report:
The Antibody-mediated Rejection market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Biogen, a biotechnology firm based in the US, has initiated dosing in its Phase III TRANSCEND trial, which is designed to evaluate felzartamab in adult kidney transplant patients experiencing late antibody-mediated rejection (AMR). The randomized, double-blind study plans to enroll around 120 participants to compare the safety and efficacy of felzartamab versus a placebo. During Part A of the 52-week trial, participants will receive nine intravenous doses of either the investigational drug or placebo over six months, with primary evaluations of safety and efficacy taking place after 24 weeks.
In October 2024, Biogen announced that the FDA has granted Breakthrough Therapy Designation (BTD) to its investigational anti-CD38 monoclonal antibody, felzartamab, for the treatment of late antibody-mediated rejection (AMR) in kidney transplant recipients. This designation highlights felzartamab’s promise as a potential new therapy for a serious condition that jeopardizes transplant outcomes.
In March 2024, Human Immunology Biosciences (HI-Bio™), a biotech firm in the clinical stage, specializing in tailored treatments for individuals grappling with severe immune-mediated disorders (IMDs), revealed that the U.S. Food and Drug Administration (FDA) has conferred Orphan Drug Designation (ODD) upon felzartamab. This designation is specifically for addressing antibody-mediated rejection (AMR) in recipients of kidney transplants.
According to DelveInsight’s estimates, in 2023, kidney, lung, and liver transplants accounted for the highest number of antibody-mediated rejection cases across the 7 major markets (7MM).
DelveInsight’s epidemiology model indicates that the United States accounted for the majority of antibody-mediated rejection (AMR) cases in 2023, comprising over 60% of the total cases across the 7MM.
Key Antibody-mediated Rejection Companies: CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others
Key Antibody-mediated Rejection Therapies: Clazakizumab, Imlifidase, VIB4920 (HZN-4920), Felzartamab, Physiologic saline solution, Belatacept, Daratumumab, BIVV020 (SAR445088), Nulojix (Belatacept), Eculizumab, and others
The Antibody-mediated Rejection epidemiology based on gender analyzed that both males and females are affected equally by Antibody-mediated Rejection
The Antibody-mediated Rejection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Antibody-mediated Rejection pipeline products will significantly revolutionize the Antibody-mediated Rejection market dynamics.
Antibody-mediated Rejection Overview
A severe post-kidney transplant complication known as antibody-mediated rejection (AMR) causes both short- and long-term damage to transplant recipients. Even with desensitization methods in place, up to one-third of extremely sensitive patients still run the risk of developing acute AMR after transplant.
Get a Free sample for the Antibody-mediated Rejection Market Report:
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
Antibody-mediated Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Antibody-mediated Rejection Epidemiology Segmentation:
The Antibody-mediated Rejection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Antibody-mediated Rejection
Prevalent Cases of Antibody-mediated Rejection by severity
Gender-specific Prevalence of Antibody-mediated Rejection
Diagnosed Cases of Episodic and Chronic Antibody-mediated Rejection
Download the report to understand which factors are driving Antibody-mediated Rejection epidemiology trends @ Antibody-mediated Rejection Epidemiology Forecast
Antibody-mediated Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-mediated Rejection market or expected to get launched during the study period. The analysis covers Antibody-mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Antibody-mediated Rejection Therapies and Key Companies
Clazakizumab: CSL Behring
Imlifidase: Hansa Biopharma
VIB4920 (HZN-4920): Horizon Therapeutics
Felzartamab: Farsad Eskandary
Physiologic saline solution: CSL Behring
Belatacept: Bristol-Myers Squibb
Daratumumab: Janssen, LP
BIVV020 (SAR445088): Sanofi
Nulojix (Belatacept): Bristol-Myers Squibb
Eculizumab: Alexion
Discover more about therapies set to grab major Antibody-mediated Rejection market share @ Antibody-mediated Rejection Treatment Market
Antibody-mediated Rejection Market Drivers
Emerging Therapy
Development of Personalized Therapy
Targeting of Novel Pathways
Increased Rate of Organ Donation
Development of Gene therapy
Antibody-mediated Rejection Market Barriers
Challenges in Designing Clinical Trials
Need for Evidence-based Treatment Guidelines
High Clinical Burden
Scope of the Antibody-mediated Rejection Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Antibody-mediated Rejection Therapeutic Assessment: Antibody-mediated Rejection current marketed and Antibody-mediated Rejection emerging therapies
Antibody-mediated Rejection Market Dynamics: Antibody-mediated Rejection market drivers and Antibody-mediated Rejection market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Antibody-mediated Rejection Unmet Needs, KOL’s views, Analyst’s views, Antibody-mediated Rejection Market Access and Reimbursement
To know more about Antibody-mediated Rejection companies working in the treatment market, visit @ Antibody-mediated Rejection Clinical Trials and Therapeutic Assessment
Table of Contents
1. Antibody-mediated Rejection Market Report Introduction
2. Executive Summary for Antibody-mediated Rejection
3. SWOT analysis of Antibody-mediated Rejection
4. Antibody-mediated Rejection Patient Share (%) Overview at a Glance
5. Antibody-mediated Rejection Market Overview at a Glance
6. Antibody-mediated Rejection Disease Background and Overview
7. Antibody-mediated Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Antibody-mediated Rejection
9. Antibody-mediated Rejection Current Treatment and Medical Practices
10. Antibody-mediated Rejection Unmet Needs
11. Antibody-mediated Rejection Emerging Therapies
12. Antibody-mediated Rejection Market Outlook
13. Country-Wise Antibody-mediated Rejection Market Analysis (2020–2034)
14. Antibody-mediated Rejection Market Access and Reimbursement of Therapies
15. Antibody-mediated Rejection Market Drivers
16. Antibody-mediated Rejection Market Barriers
17. Antibody-mediated Rejection Appendix
18. Antibody-mediated Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
